clarithromycin has been researched along with Kahler Disease in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 9 (24.32) | 29.6817 |
| 2010's | 23 (62.16) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, S; Hino, H; Hiramoto, M; Kazama, H; Miyazawa, K; Moriya, S; Takano, N | 1 |
| Alegre, A; Arguiñano, JM; Arnao, M; Bladé, J; Calasanz, MJ; Casanova, M; Cedena, MT; Coleman, M; Cortés-Rodríguez, M; Couto, MDC; de Arriba, F; de la Rubia, J; Encinas, C; Escalante, F; García-Sánchez, R; Garzón, S; Gironella, M; González, E; González, MS; González-Calle, V; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín, J; Martín, ML; Martín-Sánchez, G; Mateos, MV; Niesvizky, R; Ocio, EM; Oriol, A; Paiva, B; Pérez-Persona, E; Puig, N; Ríos, R; Rosiñol, L; San-Miguel, JF; Teruel, AI; Vale, AM | 1 |
| Allan, JN; Boussi, L; Boyer, A; Coleman, M; Ely, S; Flicker, K; Forsberg, PA; Jayabalan, D; Lakritz, S; Liotta, B; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Ribadeneyra, D; Rossi, AC | 1 |
| Becker, PS; Bensinger, W; Holmberg, LA | 1 |
| Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M | 1 |
| Abumiya, M; Kanno, S; Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N | 1 |
| Byrne, AL; Chai, KY; Morison, IM | 1 |
| Zadik, Y | 1 |
| Abildgaard, N; Andersen, CL; Do, T; Frederiksen, H; Frølund, UC; Gregersen, H; Jarden, M; Klausen, TW; Kristensen, IB; Nielsen, LK; Vangsted, AJ | 1 |
| Boyer, A; Coleman, M; Forsberg, PA; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Perry, A; Rossi, AC; Tegnestam, L | 1 |
| Abe, A; Che, XF; Gotoh, A; Inazu, M; Kawaguchi, T; Komatsu, S; Miyazawa, K; Moriya, S; Tomoda, A | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Ishizawa, K; Kato, H; Katsuoka, Y; Okitsu, Y; Onishi, Y; Takagawa, M | 1 |
| Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F | 1 |
| Borrello, I; Ghosh, N; Huff, CA; Tucker, N; Wozney, J; Zahurak, M | 1 |
| Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L | 1 |
| Abe, T; Fujii, S; Jomen, W; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Sakurai, T; Sato, M; Usami, M; Yamada, M; Yoshida, M | 1 |
| Che, XF; Gotoh, A; Hiramoto, M; Hirota, A; Inazu, M; Kawai, Y; Kokuba, H; Komatsu, S; Miyazawa, K; Moriya, S; Yamasaki, K | 1 |
| Qiu, XH; Zhai, YP | 1 |
| Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S | 1 |
| Cao, HQ; Li, HQ; Mei, JG; Qiu, XH; Shao, JJ | 1 |
| Coleman, M; Mark, TM | 1 |
| Avni, B; Barshay, Y; Benyamini, N; Ganzel, C; Gatt, ME; Goldschmidt, N; Gural, A; Lavie, D; Libster, D; Shaulov, A | 1 |
| Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F | 1 |
| Boyd, K; Clarke, P; Drake, M; Hull, DR; Jones, FC; Kettle, PJ; Morris, TC; Morrison, A; O'Reilly, P; Quinn, J | 1 |
| Agrawal, YP; Cesarman, E; Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furman, RR; Jayabalan, D; Lee, JW; Lent, R; Leonard, JP; Mark, T; Matthew, S; Mazumdar, M; Niesvizky, R; Pearse, RN; Wang, YL | 1 |
| Chen-Kiang, S; Coleman, M; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Jayabalan, DS; Kumar, S; Kyle, RA; Lacy, MQ; Leonard, J; Lust, JA; Mark, T; Niesvizky, R; Pearse, R; Rajkumar, SV; Roy, V; Stewart, AK; Witzig, TE | 1 |
| Hata, H; Kikukawa, Y; Mitsuya, H; Nakamura, M; Takeya, M | 1 |
| Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F | 1 |
| Coleman, M; Leonard, J; Lyons, L; Michaeli, J; Nahum, K; Niesvizky, R; Pearse, R; Pekle, K | 1 |
| Aboulafia, DM | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F | 1 |
| Attal, M; Bataille, R; Bouilly, I; Facon, T; Harousseau, JL; Huynh, A; Legros, L; Milpied, N; Moreau, P; Sotto, JJ | 1 |
| Al-Berouti, BM; Meharchand, J; Stewart, AK; Sutton, DM; Trudel, S | 1 |
| Morris, TC; Morrison, J; Ranaghan, L | 1 |
| Bodenizza, C; Carella, AM; Carotenuto, M; Falcone, A; Musto, P; Sanpaolo, G | 1 |
4 review(s) available for clarithromycin and Kahler Disease
| Article | Year |
|---|---|
[Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2017 |
[Progress of research on clarithromycin for treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Multiple Myeloma; Thalidomide | 2015 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide | 2015 |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Bone Marrow Examination; CD4 Lymphocyte Count; Clarithromycin; Dexamethasone; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome; Viral Load; Viral Matrix Proteins | 2003 |
11 trial(s) available for clarithromycin and Kahler Disease
| Article | Year |
|---|---|
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2021 |
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Treatment Outcome | 2021 |
Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Clinical Protocols; Cyclophosphamide; Denmark; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Treatment Outcome | 2019 |
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome | 2019 |
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cells; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Quality of Life; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clarithromycin; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide; Thrombocytopenia | 2010 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Time Factors | 2008 |
Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM)
Topics: Anti-Bacterial Agents; Clarithromycin; Female; Humans; Male; Middle Aged; Multiple Myeloma | 1999 |
Phase II trial of clarithromycin and pamidronate therapy in myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Clarithromycin; Diphosphonates; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pamidronate; Protein Synthesis Inhibitors; Treatment Outcome | 2001 |
22 other study(ies) available for clarithromycin and Kahler Disease
| Article | Year |
|---|---|
Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression.
Topics: Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Clarithromycin; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Stromal Cells | 2023 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Clarithromycin; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Diabetes Mellitus; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Humans; Male; Multiple Myeloma; Pneumonia; Roxithromycin; Treatment Outcome | 2018 |
Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients.
Topics: Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clarithromycin; Drug Administration Schedule; Humans; Multiple Myeloma; Osteolysis | 2018 |
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
Topics: Animals; Apoptosis; Autophagy; Azithromycin; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Endoplasmic Reticulum Stress; Erythromycin; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Mice; Multiple Myeloma; Pyrazines; Transcription Factor CHOP | 2013 |
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide | 2014 |
[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Immunoglobulin A; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2015 |
Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells.
Topics: Clarithromycin; Drug Synergism; Humans; Immunosuppressive Agents; Multiple Myeloma; Signal Transduction; Thalidomide | 2016 |
It's Time to Take Clarithromycin Seriously in Multiple Myeloma.
Topics: Clarithromycin; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide | 2016 |
Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Disease Progression; Fatigue; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Infections; Male; Middle Aged; Multiple Myeloma; Protein Synthesis Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome | 2017 |
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Clarithromycin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Thalidomide | 2008 |
Clarithromycin attenuates autophagy in myeloma cells.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Survival; Clarithromycin; Dose-Response Relationship, Drug; Humans; Lysosomes; Microtubule-Associated Proteins; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Time Factors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Vacuoles | 2010 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2013 |
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Disease Progression; Female; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Thalidomide; Time Factors; Treatment Outcome; Waldenstrom Macroglobulinemia | 2002 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 1999 |
Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protein Synthesis Inhibitors; Treatment Outcome | 2002 |